BD Completes Acquisition of Critical Care from Edwards Lifesciences
BD (Becton, Dickinson and Company) has completed the acquisition of Edwards Lifesciences' Critical Care product group, now renamed as BD Advanced Patient Monitoring. This acquisition expands BD's portfolio of smart connected care solutions with leading monitoring technologies and AI-enabled clinical decision tools. The combination of BD's new advanced monitoring and existing infusion platforms enables future innovation opportunities for closed-loop monitoring and treatment.
Key points:
- BD Advanced Patient Monitoring will be based in Irvine, California
- It becomes part of BD's Medical segment
- Katie Szyman will continue as worldwide president
- The acquisition is expected to have an immaterial impact on BD's fiscal year 2024 guidance
BD (Becton, Dickinson and Company) ha completato l'acquisizione del gruppo prodotti Critical Care di Edwards Lifesciences, ora rinominato BD Advanced Patient Monitoring. Questa acquisizione amplia il portafoglio di soluzioni di assistenza intelligente connesse di BD, con tecnologie di monitoraggio all'avanguardia e strumenti di decisione clinica abilitati all'IA. La combinazione delle nuove piattaforme di monitoraggio avanzato di BD e delle esistenti piattaforme di infusione offre opportunità di innovazione futura per il monitoraggio e il trattamento a circuito chiuso.
Punti chiave:
- BD Advanced Patient Monitoring avrà sede a Irvine, California
- Diventa parte del segmento medico di BD
- Katie Szyman continuerà come presidente mondiale
- Si prevede che l'acquisizione avrà un impatto immateriale sulle linee guida di BD per l'anno fiscale 2024
BD (Becton, Dickinson and Company) ha completado la adquisición del grupo de productos Critical Care de Edwards Lifesciences, que ahora se denomina BD Advanced Patient Monitoring. Esta adquisición amplía el portafolio de soluciones de atención conectada inteligente de BD, con tecnologías de monitoreo líderes y herramientas de decisión clínica habilitadas por IA. La combinación de las nuevas plataformas de monitoreo avanzado de BD y las plataformas de infusión existentes permite futuras oportunidades de innovación para el monitoreo y tratamiento en circuito cerrado.
Puntos clave:
- BD Advanced Patient Monitoring tendrá su sede en Irvine, California
- Se convierte en parte del segmento médico de BD
- Katie Szyman continuará como presidenta mundial
- Se espera que la adquisición tenga un impacto inmaterial en la guía fiscal de BD para 2024
BD (Becton, Dickinson and Company)는 Edwards Lifesciences의 중환자 치료 제품 그룹을 인수하였습니다, 현재는 BD 고급 환자 모니터링이라고 이름이 변경되었습니다. 이번 인수는 BD의 스마트 연결 치료 솔루션 포트폴리오를 선도하는 모니터링 기술과 AI 기반 임상 의사 결정 도구로 확대합니다. BD의 새로운 고급 모니터링과 기존의 주입 플랫폼의 결합은 닫힌 루프 모니터링 및 치료를 위한 미래 혁신 기회를 가능하게 합니다.
주요 사항:
- BD 고급 환자 모니터링은 캘리포니아주 어바인에 본사가 위치합니다
- BD의 의료 부문에 포함됩니다
- 케이티 시먼은 전 세계 회장직을 계속 수행합니다
- 이번 인수는 BD의 2024 회계 연도 지침에 물질적 영향을 미치지 않을 것으로 예상됩니다
BD (Becton, Dickinson and Company) a achevé l'acquisition du groupe de produits Critical Care d'Edwards Lifesciences, qui est désormais renommé BD Advanced Patient Monitoring. Cette acquisition élargit le portefeuille de solutions de soins connectés intelligents de BD avec des technologies de surveillance avancées et des outils de décision clinique habilités par l'IA. La combinaison des nouvelles plateformes de surveillance avancée de BD et des plateformes d'infusion existantes offre de futures opportunités d'innovation pour la surveillance et le traitement en boucle fermée.
Points clés :
- BD Advanced Patient Monitoring sera basé à Irvine, Californie
- Il fait partie du segment médical de BD
- Katie Szyman continuera en tant que présidente mondiale
- On s'attend à ce que l'acquisition ait un impact immatériel sur les prévisions de BD pour l'exercice fiscal 2024
BD (Becton, Dickinson and Company) hat die Übernahme der Critical Care Produktgruppe von Edwards Lifesciences abgeschlossen, die jetzt in BD Advanced Patient Monitoring umbenannt wurde. Diese Übernahme erweitert das Portfolio von BD um intelligente, vernetzte Pflege-Lösungen mit führenden Überwachungstechnologien und KI-gestützten klinischen Entscheidungswerkzeugen. Die Kombination von BDs neuen fortschrittlichen Überwachungs- und bestehenden Infusionsplattformen ermöglicht zukünftige Innovationsmöglichkeiten für geschlossenes Monitoring und Behandlung.
Wichtige Punkte:
- BD Advanced Patient Monitoring wird seinen Sitz in Irvine, Kalifornien haben
- Es wird Teil des medizinischen Segments von BD
- Katie Szyman wird weiterhin als weltweite Präsidentin im Amt bleiben
- Es wird erwartet, dass die Übernahme keinen wesentlichen Einfluss auf die Prognose von BD für das Geschäftsjahr 2024 haben wird
- Expansion of BD's portfolio with leading monitoring technologies and AI-enabled clinical decision tools
- Potential for future innovation in closed-loop monitoring and treatment
- Integration of combined company data sets and interoperability capabilities
- Retention of experienced leadership with Katie Szyman continuing as worldwide president
- None.
The acquisition of Edwards Lifesciences' Critical Care product group by BD is a strategic move that expands BD's portfolio in the smart connected care solutions market. This transaction is likely to have a positive long-term impact on BD's financial performance and market position.
The integration of BD's existing infusion platforms with the newly acquired monitoring technologies creates opportunities for synergies and innovation, particularly in closed-loop systems. This could lead to increased revenue streams and market share in the growing field of AI-enabled healthcare solutions.
While the immediate financial impact is described as "immaterial" to FY2024 guidance, investors should monitor for potential revenue growth and margin expansion in the coming years as BD leverages this acquisition to strengthen its position in the medical technology sector.
BD's acquisition of Edwards Lifesciences' Critical Care group marks a significant advancement in smart connected care solutions. The combination of BD's infusion systems with Advanced Patient Monitoring's technologies creates a powerful synergy, enabling the development of closed-loop systems for hemodynamic monitoring and drug administration.
The integration of AI and machine learning in these systems represents a major leap forward in patient care. It allows for more precise, data-driven decision-making in critical care settings. The potential for predictive and prescriptive algorithms to guide treatment could significantly improve patient outcomes and reduce healthcare costs.
This move positions BD at the forefront of the AI-driven healthcare revolution, aligning with the industry's shift towards more autonomous and intelligent medical solutions. It's a forward-thinking strategy that could set new standards in patient monitoring and treatment in intensive care units and operating rooms.
- Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools
- Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities
- Business renamed as BD Advanced Patient Monitoring, will be based in
Irvine, Calif. and become part of BD Medical segment - Katie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide president
BD Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands BD's portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline. BD Advanced Patient Monitoring's technologies are often used simultaneously with the BD Alaris™ Infusion System in the operating room or intensive care units. The combination of BD's new advanced monitoring and existing infusion platforms enables future innovation opportunities for closed-loop hemodynamic monitoring and IV fluid and medication administration by integrating combined company data sets and interoperability capabilities.
"The health care industry is being redefined by AI, robotics, and autonomous solutions, and our team continues to accelerate the application of these new technologies to improve the quality and cost of patient care around the world," said Tom Polen, chairman, chief executive officer and president of BD. "Today, BD is proud to welcome BD Advanced Patient Monitoring, whose leading technologies, AI-enabled solutions and strong innovation pipeline expand our portfolio of smart, connected care solutions, create significant value for customers, and put BD at the forefront of enabling the future of health care."
BD Advanced Patient Monitoring's portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors and monitors. Its smart technologies are driven by advanced data analytics with machine learning and AI-based predictive and prescriptive algorithms to help clinicians better understand current and future patient conditions and provide clinical decision support tools.
BD Advanced Patient Monitoring will operate as a separate business unit within BD's Medical segment to align with its smart connected care approach, and it will maintain its presence in
The completion of the acquisition is expected to have an immaterial impact to the previously disclosed BD fiscal year 2024 guidance provided in the August 1 third quarter earnings news release. For additional information about the transaction, please reference the Investor Presentation and Transaction Announcement Press Release issued on June 3, 2024, both available on the Investor page on BD.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo.
Forward-Looking Statements
This press release contains forward-looking statements (as defined under Federal securities laws) regarding the anticipated benefits of the acquisition of Edwards Lifesciences' Critical Care product group. These statements are based on the current expectations of BD management and are subject to a number of risks and uncertainties regarding the business and the acquisition, and actual results may differ materially from any anticipated results described, implied or projected in any forward-looking statement. These risks and uncertainties include, but are not limited to, risks relating to the integration of the Critical Care Product group's operations, products and employees into BD and the time and resources required to do so and the possibility that the anticipated benefits of the acquisition will not be realized or will not be realized within the expected timeframe; the loss of key senior management or other associates; competitive factors, including the development of new technologies by other companies and pricing and market share pressures; changes in healthcare or other governmental regulation; risks relating to the ability to maintain favorable supplier arrangements and relationships; changes in regional, national or foreign economic conditions, as well as other factors discussed in BD's filings with the Securities Exchange Commission. BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.
Contacts: | ||
Media: | Investors: | |
Troy Kirkpatrick | Adam Reiffe | |
VP, Public Relations | Sr. Director, Investor Relations | |
858.617.2361 | 201.847.6927 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-completes-acquisition-of-critical-care-from-edwards-lifesciences-302237204.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What company did BD (BDX) acquire in September 2024?
How will the acquisition impact BD's (BDX) fiscal year 2024 guidance?
What are the main products included in BD's (BDX) newly acquired Advanced Patient Monitoring portfolio?
Who will lead BD Advanced Patient Monitoring following the acquisition by BD (BDX)?
